Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. SexMed

Challenges With Flibanserin as Treatment for Hypoactive Sexual Desire Disorder

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    Flibanserin was one of the first FDA-approved medications for treatment of Hypoactive Sexual Desire Disorder in pre-menopausal women. But the drug's effectiveness has frequently been called into question, and the known side effects such as fainting, dizziness, and low blood pressure, many of which were found to be exacerbated by alcohol and hormonal contraception, created concerns for clinicians and patients alike.  

    Host Dr. Michael Krychman talks with guest Dr. Lisa Larkin, women’s health internist and Director of the Women's Health Center at the University of Cincinnati College of Medicine, about the “Pink Viagra" pill, concerns around its safety and effectiveness, and the diagnosis and treatment of HDSS.

Recommended
Details
Presenters
Comments
  • Overview

    Flibanserin was one of the first FDA-approved medications for treatment of Hypoactive Sexual Desire Disorder in pre-menopausal women. But the drug's effectiveness has frequently been called into question, and the known side effects such as fainting, dizziness, and low blood pressure, many of which were found to be exacerbated by alcohol and hormonal contraception, created concerns for clinicians and patients alike.  

    Host Dr. Michael Krychman talks with guest Dr. Lisa Larkin, women’s health internist and Director of the Women's Health Center at the University of Cincinnati College of Medicine, about the “Pink Viagra" pill, concerns around its safety and effectiveness, and the diagnosis and treatment of HDSS.

Schedule15 Dec 2024